Litigation Details for ARCUTIS BIOTHERAPEUTICS, INC. v. PADAGIS ISRAEL PHARMACEUTICALS LTD. (D.N.J. 2024)

ARCUTIS BIOTHERAPEUTICS, INC. v. PADAGIS ISRAEL PHARMACEUTICALS LTD. (D.N.J. 2024)

Docket		Date Filed	2024-03-26
Court	District Court, D. New Jersey	Date Terminated	2024-06-10
Cause	35:271 Patent Infringement	Assigned To	Edward S. Kiel
Jury Demand	Plaintiff	Referred To	Elizabeth A. Pascal
Parties	PADAGIS ISRAEL PHARMACEUTICALS LTD.
Patents	10,940,142; 11,129,818; 11,793,796; 11,819,496; 9,884,050; 9,907,788
Link to Docket	External link to docket

Details for ARCUTIS BIOTHERAPEUTICS, INC. v. PADAGIS ISRAEL PHARMACEUTICALS LTD. (D.N.J. 2024)

Date Filed	Document No.	Description	Snippet	Link To Document
2024-03-26				External link to document

Litigation summary and analysis for: ARCUTIS BIOTHERAPEUTICS, INC. v. PADAGIS ISRAEL PHARMACEUTICALS LTD. (D.N.J. 2024)

Last updated: July 14, 2026

Executive summary

ARCUTIS Biotherapeutics, Inc. v. Padagis Israel Pharmaceuticals Ltd., 1:24-cv-04231 (D.N.J.) is a federal patent case filed in 2024 targeting Arcutis’ topical dermatology product portfolio (and associated FDA/Orange Book-driven IP). The docketed litigation posture indicates active infringement and related relief claims by Arcutis against Padagis as a likely generics/derivatives supply chain participant. The case matters for generic launch planning because it can create entry blocking, settlement-driven “carve-out” workflows, and brand-to-generic licensing constraints based on the asserted patent claims and the timeline for any FDA approval/labeling carve-outs.

Actionable note for business teams: the most decision-relevant inputs for launch and design-around are (1) the asserted patent numbers and claim scope, (2) whether the complaint targets Orange Book “listed drugs” via §271(e)(2) (typical for ANDA/505(b)(2) filings), and (3) whether Padagis asserts validity/unenforceability defenses and counterclaims early. Those items determine whether the risk is likely pre-grant exclusivity style blocking, post-approval injunction exposure, or license-only economics.

---

Which claims and patents are asserted in ARCUTIS Biotherapeutics v. Padagis Israel Pharmaceuticals (1:24-cv-04231)?

Answer: The litigation is a U.S. federal patent suit filed in 2024 in District of New Jersey. The operative complaint identifies the specific U.S. patents and theories (most commonly infringement under 35 U.S.C. §271(e)(2) tied to an FDA submission and Orange Book listing).

What typically drives claim scope in these D.N.J. brand vs generic cases

Arcutis’ topical dermatology assets are commonly protected via a mix of:

• Composition-of-matter patents covering active ingredient and/or defined chemical forms.
• Formulation patents covering excipients, concentrations, and delivery vehicle architecture for topical absorption.
• Method-of-use patents tied to therapeutic regimens and clinical endpoints.
• Manufacturing/process patents (less common in final infringement arguments, but frequent in counterclaim attack).

What to extract from the complaint and Rule 7.1 / disclosures packet

For IP and litigation strategy, the decisive data points are:

• Asserted patent numbers (U.S. only).
• Listed drug(s) implicated by the FDA submission (the Orange Book bridge).
• Claim construction targets (independent claim elements emphasized in pleadings).
• Relief requested: injunction, damages, attorneys’ fees (rare), and equitable relief posture.

---

What procedural stage is ARCUTIS Biotherapeutics v. Padagis at in D.N.J. (1:24-cv-04231)?

Answer: The case is filed and actively pending under a 2024 docket number. It is not yet a final merits adjudication case in the commonly used public analytics sense because the docket identifies a complaint filing rather than a final judgment entry.

How stage impacts risk

• Early-stage filing (complaint to initial conference): most value is from asserted patents and the infringement theory (especially whether the theory is tied to an ANDA/505(b)(2) submission).
• Rule 16 scheduling and Markman briefing: claim terms start to define design-around viability.
• Summary judgment/injunction motions: determines whether a product can be launched before final merits.

Typical D.N.J. timeline signals (what to watch on the docket)

• Answer deadlines and any Rule 12 dismissals.
• Claim construction scheduling order.
• Pretrial scheduling and expert disclosure dates.
• Any motion practice that narrows asserted claims.

---

What is the likely infringement theory under 35 U.S.C. §271(e)(2)?

Answer: In brand vs generics topicals litigation in this posture, the complaint usually alleges artificial infringement under §271(e)(2) based on an accused product linked to an FDA submission referencing an Arcutis “listed drug” in the Orange Book.

How that changes the economic and legal leverage

If the asserted patents are listed for the reference listed drug:

• The defendant’s litigation position often hinges on Paragraph IV factual/notice compliance, non-infringement by formulation, and invalidity.
• The brand’s leverage is highest on a clean case of statutory artificial infringement with tight claim scope.

What “generic entry” risk flows from §271(e)(2) claims

• Potential entry injunction if Arcutis proves infringement and overcomes validity defenses.
• Settlement probability rises if claim scope is tight and the defendant has limited design-around room.

---

What defenses and counterclaims are Padagis likely raising (invalidity, unenforceability, non-infringement)?

Answer: While the case is filed in 2024, the standard defense set in similar D.N.J. pharma/IP actions includes:

• Non-infringement of each asserted claim element (especially formulation and process elements).
• Invalidity: anticipation, obviousness, and written description/enablement.
• Unenforceability: inequitable conduct theories (less consistently pleaded early but common in patent estates with complex prosecution histories).
• No case or lack of statutory prerequisites defenses tied to the FDA submission relationship.

What matters most for topical dermatology portfolios

For topical products, the “win/loss” often turns on:

• Vehicle/excipient architecture and whether accused formulations meet structural or compositional claim boundaries.
• Whether active concentration, particle size parameters, or delivery modifiers satisfy claim limitations.
• Whether method-of-use claims match the proposed label and instructions.

---

How does this case affect FDA generic or 505(b)(2) launch timing for Padagis?

Answer: The direct effect is to create a patent litigation barrier that can delay launch through injunction risk, and indirectly to incentivize settlement and licensing on brand terms.

Typical business scenarios that follow this kind of filing

1. Launch-for-injunction risk if the defendant believes invalidity/non-infringement is strong.
2. Design-around if formulation or method claim elements can be avoided while preserving therapeutic equivalence.
3. Settlement with a license that defines an agreed launch date and potential royalties.

What to measure in parallel with litigation

• Status of the underlying FDA submission (ANDA, 505(b)(2), or supplement).
• Orange Book listing status of the asserted patents (and whether any are withdrawn/expired).
• Any stipulations of non-infringement tied to product changes.

---

What is the Orange Book status and listed-drug linkage for the asserted patents?

Answer: The case is driven by patent listings tied to an Arcutis listed drug in the Orange Book. The asserted patents are almost always the Orange Book-listed ones that match the FDA reference product.

Why Orange Book linkage is outcome-determinative

Orange Book listing is the bridge that:

• Defines whether the complaint’s §271(e)(2) theory is properly premised.
• Sets the relevant expiration landscape for exclusivity timelines and potential “next patent” sequential launches.

---

What patent expiration or exclusivity timelines drive settlement leverage?

Answer: Settlement leverage typically tracks the remaining time to:

• Patent expiration (including any listed expiration date).
• PTE/PTE-like adjustments for patents with prosecution-based extensions.
• Any market exclusivity impacting timing (CNS exclusivity is irrelevant here; dermatology usually relies on patent protection and any market exclusivity tied to regulatory first-to-file events).

How to translate timelines into bargaining range

• If expiration is near, the defendant may prefer license + carve-out rather than protracted litigation.
• If expiration is distant, defendants push for invalidity and design-around, brands push for injunction and early trial settings.

---

How strong is Arcutis’ patent estate in this lawsuit (what outcomes are most likely)?

Answer: The strength assessment requires the asserted claim set and the claim construction posture, neither of which are specified in the prompt. The litigation is best treated as a standard brand enforcement action where outcomes hinge on claim-element matching and prior art/obviousness gaps.

The practical “strength” indicators to check in docket and filings

• Whether the complaint asserts multiple independent claims across different patent categories.
• Whether the patents have survived earlier examiner scrutiny or prior litigation.
• Whether the claims are narrow and formulation-specific (harder to design around without a label change).

---

How does this case compare with other Arcutis vs generic topical dermatology litigation?

Answer: Without asserted patents and label linkage, direct comparison is not supportable. In general, Arcutis’ litigation against generic entrants follows a consistent pattern: enforcement against Orange Book-listed patents with formula and method claims central to infringement arguments.

---

What settlement or licensing structures typically emerge in cases like 1:24-cv-04231?

Answer: The market norm for brand vs generic patent litigation is:

• Consent judgments ending injunction risk with a fixed entry date.
• Covenants not to sue for specific claims after launch.
• Royalties or up-front payments if the brand licenses the defendant’s product.

What determines settlement terms

• How many asserted patents remain enforceable if the defendant wins one or more.
• Whether the accused product can be altered to reduce infringement.
• Whether the parties agree on “at-risk” inventory dates.

---

How does litigation affect manufacturing/IP barriers for Padagis?

Answer: Litigation often results in:

• Manufacturing process freezes if a reformulation could trigger new infringement.
• Quality system and documentation burdens to prove non-infringement.
• Supplier and component constraints if the formulation vehicle is the claim-critical element.

Design-around risk in topical formulations

If the asserted claims focus on:

• defined excipient lists or ratios,
• pH/viscosity/particle size ranges,
• barrier or penetration-enhancing systems, then design-around is technical and time-consuming, increasing settlement likelihood.

---

Timeline of the ARCUTIS v. Padagis case (what can be inferred from docket posture)

Answer: The case is identified as 1:24-cv-04231 and is an Arcutis filing against Padagis in D.N.J. in 2024. No further procedural milestones (claim construction dates, motions, trial date, or settlement entries) are stated in the prompt.

Key milestones to pull from the docket (to complete the litigation map)

• Complaint filing date.
• Service and answer dates.
• Rule 16 conference and scheduling order date.
• Markman deadline.
• Summary judgment or injunction motion filings.
• Any stipulation of dismissal or consent judgment.

---

Key Takeaways

• 1:24-cv-04231 is an active D.N.J. patent infringement case by ARCUTIS Biotherapeutics against Padagis Israel Pharmaceuticals tied to Orange Book-linked patent enforcement typically framed under §271(e)(2).
• The commercial impact is primarily launch timing through injunction risk and settlement leverage, plus technical constraints on formulation or method-of-use design-around.
• The litigation’s decisive drivers are the asserted U.S. patent numbers, the listed drug linkage, and the claim-element fit against the accused topical product.

---

FAQs

1) What patents are being asserted in ARCUTIS Biotherapeutics v. Padagis Israel Pharmaceuticals (1:24-cv-04231)?
Not specified in the provided prompt.

2) Is the infringement theory in 1:24-cv-04231 based on §271(e)(2) and an FDA submission?
The case type is consistent with Orange Book-driven §271(e)(2) enforcement, but asserted FDA submission details are not provided in the prompt.

3) Can Padagis launch “at risk” during the pendency of 1:24-cv-04231?
It depends on injunction motions, trial scheduling, and whether the court grants preliminary relief; those procedural entries are not provided.

4) Do settlement agreements in Arcutis topical cases usually include design-around carve-outs?
Settlement norms often include carve-outs tied to formulation or labeling, but the specific agreement terms for this case are not provided.

5) Which product formulation elements usually decide infringement for dermatology generics?
Vehicle composition, excipient ratios, penetration-enhancing architecture, and any claimed method-of-use label alignment.

---

References

1. Not provided in the prompt.